Predicting esophageal cancer response to neoadjuvant therapy with magnetic resonance imaging radiomics

Table 1 Clinical characteristics of all esophageal cancer patients

Characteristics	Non-response group	Response group	P value
Age (year)	60.38 ± 8.96	55.44 ± 7.99	0.347
Gender, n (%)			0.375
Male	78 (81.25)	31 (86.11)
Female	18 (18.75)	5 (13.89)
Location, n (%)			0.765
Upper	17 (17.71)	4 (11.11)
Middle	46 (47.92)	20 (55.56)
Lower	23 (23.95)	9 (25.00)
Middle and lower	10 (10.42)	3 (8.33)
Degree of differentiation, n (%)			0.388
Well differentiated	1 (1.04)	1 (2.78)
Moderately differentiated	74 (77.08)	29 (80.56)
Poorly differentiated	14 (14.59)	5 (13.88)
Medium to high differentiation	1 (1.04)	0 (0)
Middle to low differentiation	6 (6.25)	1 (2.78)
Length of tumor	5.54 ± 1.76	5.43 ± 1.91	0.862
CEA	3.09 (1.78, 3.26)	2.89 (1.74, 3.65)	0.47
SCCA	2.40 (0.80, 3.00)	1.70 (0.74, 1.86)	0.859

CEA: Carcinoembryonic antigen; SCCA: Squamous cell carcinoma antigen.